Sanofi Pasteur's Typhoid Vi polysaccharide vaccine

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

Salmonella InfectionsTyphoid Fever

Phase 1

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever

CompletedNCT05480800

GlaxoSmithKlineSalmonella Infections

Start: 2022-09-13End: 2025-01-07Updated: 2025-11-28

Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults

CompletedNCT05613205

GlaxoSmithKlineTyphoid Fever

Start: 2022-11-28End: 2024-04-02Updated: 2025-01-24

Related Papers

Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial.

2026-01-23